At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 14 enrolled
Drug / intervention
AGN-151597drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase I/IIa, Open-Label, Dose-Escalation Study of Safety and Tolerability of Intravitreal RST-001 in Patients With Advanced Retinitis Pigmentosa (RP)
In Brief
A Phase 2 clinical trial evaluating AGN-151597 for Advanced Retinitis Pigmentosa. Completed, enrolled 14 participants across 4 sites.
Detailed Summary
All participants in phase 1 and phase 2a had hand motion visual acuity or worse. If efficacy was demonstrated from phase 1, better vision subjects could be enrolled; however, efficacy was not demonstrated.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Retinitis Pigmentosa
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedSep 2015
Enrollment StartDec 2015
Primary CompletionJun 2020
Study CompletionOct 2024
TodayJul 2026
First PostedSep 22, 2015
Enrollment StartDec 14, 2015
Primary CompletionJun 1, 2020
Study CompletionOct 21, 2024
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 10.8 years ago
Interventions
AGN-151597drug
AGN-151597 is a gene therapeutic delivered by intravitreal injection